Biotech

Latest Articles

Capricor sells Europe civil rights to late-stage DMD therapy for $35M

.Possessing presently scooped up the U.S. rights to Capricor Therapeutics' late-stage Duchenne muscu...

FDA junks adcomm for Applied's uncommon condition medicine

.After pushing back the selection meeting for Applied Therapeutics' metabolic problem medicine govor...

Novo inks $600M NanoVation offer to examine hereditary medications ex-liver

.Novo Nordisk is actually continuing its own press right into genetic medications, accepting to pay ...

Innovent links cytokine to colorectal cancer responses

.Innovent Biologics has actually helped make the instance that its gate inhibitor-cytokine fusion pr...

Merck, Daiichi ADC attacks objective in period 3 lung cancer cells research study

.A period 3 trial of Daiichi Sankyo and also Merck &amp Co.'s HER3-directed antibody-drug conjugate ...

Rakovina grows AI focus along with collab to choose cancer cells targets

.5 months after Rakovina Therapies rotated towards artificial intelligence, the cancer-focused biote...

Ascendis' dwarfism medicine favorites in period 3, intimidates BioMarin

.Ascendis Pharma has emerged as a possible danger to BioMarin's Voxzogo, reporting phase 3 growth co...

Despite ph. 3 overlook, Alkeus views path in advance for eye condition property

.Though Alkeus Pharmaceuticals' oral eye disease asset failed to substantially minimize geographic d...

Kairos goes social along with $6M IPO to fund tests of cancer medicine

.Along with a trio of biotechs attacking the Nasdaq on Friday, it was actually quick and easy to ove...

Vaccine as well as Keytruda combo helpful in squamous tissue cancer

.Immune checkpoint preventions are actually the superheroes of cancer cells treatment. Medications l...

Cue Biopharma queues up J&ampJ vet as CBO-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of considerable leadership hirings, firings and...

Regeneron's Opdualag competitor presents 57% reaction cost

.Regeneron is actually back with long-lasting follow-up for its own LAG-3 inhibitor as well as PD-1 ...

AstraZeneca articles information on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early check out the performance of its internal antibody-drug...

iTeos- GSK's TIGIT celebrity reveals relevant remodeling

.After introducing a phase 3 launch based upon beneficial midstage end results, iTeos as well as GSK...

More joint FDA may speed up uncommon ailment R&ampD: record

.The FDA needs to be a lot more available as well as joint to discharge a rise in approvals of uncom...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It's an unusually hectic Friday for biotech IPOs, with Zenas BioPharma, MBX as well as Bicara Thera...

Atea's COVID antiviral fails to stop hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has stopped working another COVID-19 test, but the biotech still ho...

Neurocrine's quote to save mental illness prospect falls short

.Neurocrine Biosciences' mental illness system pivot has actually stopped working. The biotech was u...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has actually brought in a late entry to the radioligand party, paying one hundred million eu...

F 2G rears $100M for 2nd effort to receive brand new antifungal to market

.After F2G's 1st effort to get a brand-new lesson of antifungal to market was thwarted by the FDA, t...